Free Trial
NASDAQ:ALEC

Alector Q1 2025 Earnings Report

Alector logo
$1.30 +0.08 (+6.56%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$1.31 +0.01 (+0.77%)
As of 05/2/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alector EPS Results

Actual EPS
N/A
Consensus EPS
-$0.46
Beat/Miss
N/A
One Year Ago EPS
N/A

Alector Revenue Results

Actual Revenue
N/A
Expected Revenue
$4.25 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Alector Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Friday, May 9, 2025
Conference Call Time
4:00PM ET

Conference Call Resources

Alector Earnings Headlines

Analysts Set Alector, Inc. (NASDAQ:ALEC) Price Target at $3.50
Alector completes enrollment in PROGRESS-AD Phase 2 trial of AL01
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
Alector Provides Executive Leadership Update
See More Alector Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alector? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alector and other key companies, straight to your email.

About Alector

Alector (NASDAQ:ALEC), a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

View Alector Profile

More Earnings Resources from MarketBeat